Pure client since 2007. Scope of work for AVEO (NASDAQ: AVEO) includes integrated corporate and product communications encompassing PR, IR and digital media.

Pure client since 2010. Leading strategic corporate communications, branding and employee communications activities for this private company focused on cancer metabolism, a promising new frontier of cancer research.

Pure client since 2007. Leading PR efforts and launched new website to support private RNA interference company developing novel therapeutic agents and related drug delivery systems in multiple disease areas based on its proprietary Dicer Substrate Technology™ platform and Dicer Substrate siRNA (DsiRNA) molecules.

Pure client since 2008. Scope of work for GI Dynamics, Inc. (ASX: GID) includes integrated corporate, product and marketing communications initiatives spanning PR, IR and digital media.

Pure client since 2008. Spearheading corporate and product focused communication strategies for the worldwide leader in medical imaging, with headquarters in North Billerica, Massachusetts, and nearly 700 employees worldwide with offices in Puerto Rico, Canada, and Australia.

Pure client since 2010. Provided strategic counsel and support through the company's 2011 IPO (NASDAQ:PCRX) and executing an integrated corporate communications program encompassing IR, PR and product communications to support Pacira's commercial launch of its lead product EXPAREL™, which has completed Phase 3 clinical development for postoperative analgesia by infiltration.

Pure client since 2006. Efforts include multi-faceted communications programming and counsel spanning preclinical and clinical product development, business development and patient advocacy initiatives for this New Jersey-based biotech company focused on post-transcriptional control/mRNAi drug discovery.

SAGE Therapeutics is a central nervous system (CNS) product focused company building a portfolio of new therapies to meet the growing unmet need in a range of CNS disorders, including schizophrenia, depression, pain, and traumatic brain injury. SAGE Therapeutics' proprietary Positive and Negative Allosteric Modulator (PANAM) chemistry platform targets the primary excitatory and inhibitory neurotransmitter systems in the brain and enables the development of allosteric modulators that fine tune and balance neuronal activity that is disrupted in CNS disorders.

Sunshine Heart is a global medical device company committed to the commercialization of the C-Pulse Heart Assist System, an implantable, non-blood contacting, heart assist therapy for the treatment of moderate to severe heart failure which can be implanted using a minimally invasive procedure. C-Pulse is designed to relieve the symptoms of heart failure through the use of counter-pulsation technology which enables an increase in cardiac output, an increase in coronary blood flow and a reduction in the heart’s pumping load.

Third Rock Ventures is a venture capital firm founded in 2007 with the mission to launch transformative life sciences companies. With more than $800 million and two funds under management, the firm is focused on working with passionate entrepreneurs to build exceptional companies working in areas of disruptive science that will make a difference in the lives of patients. Pure Communications provides strategic communications counsel and graphic/web design services to the firm.

Warp Drive Bio is driving the reemergence of natural products in the era of genomics to create breakthrough treatments that make an important difference in the lives of patients. Built upon the belief that nature is the world’s most powerful medicinal chemist, Warp Drive Bio is deploying a battery of state-of-the-art technologies to access powerful drugs that are now hidden within microbes.

Pure client since 2007. Scope of work for AVEO (NASDAQ: AVEO) includes integrated corporate and product communications encompassing PR, IR and digital media.